Companies Cryptocurrencies
Ayala Pharmaceuticals Inc
Ayala Pharmaceuticals Inc
Exchange: NasdaqGS
IPO Date: 08/05/2020
CEO: Dr. Roni Mamluk
Biotechnology Healthcare đź”—
  • AYLA
  • 1.12
  • 15775536
    market cap
  • 0.00999999
If you bought

shares of Ayala Pharmaceuticals Inc (AYLA) on
You would have made
Old Price $12 Current Price $12

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company. It is focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company’s portfolio of product candidates include AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. The Company’s lead product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor (GSI). It is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC) for patients bearing Notch-activating mutations. The Company refer this trial as the ACCURACY trial. The Company uses advanced sequencing to identify patients with Notch-activating mutations, an approach that will enable it to target the patient population with cancers.

Address: 1313 N Market St Ste 5100 Wilmington DELAWARE 7670104

Stay updated.